Streetbeat News

Earnings

IZEA

IZEA Worldwide reported Q3 earnings with a loss of $0.13 per share, significantly missing the consensus estimate of a $0.07 loss per share. This represents a 225% increase in losses compared to the same period last year. Quarterly sales were $7.89M, falling short of the expected $8.50M, and marking a 27.07% decrease from the previous year's sales.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 9:02 pm

QRHC

Quest Resource Holding Corporation reported Q3 adjusted earnings per share (EPS) of $0.02, beating the estimate of $(0.01). However, revenue was $70.4M, falling short of the $77.698M estimate.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 9:01 pm

GTBIF

MRMD

TLLTF

VRNOF

Zuanic & Associates released reports on Verano Holdings, TILT Holdings, MariMed Inc., and Green Thumb Industries, analyzing their Q3 results and future outlook. Verano anticipates a 4Q decline due to various factors but shows positive cash flow trends. TILT exceeded 3Q expectations and is positioned for growth with new partnerships. MariMed's 4Q guidance is reduced due to expansion delays but has a positive outlook for CY24. Green Thumb's 3Q update lacks sales guidance for 4Q, but increased capital expenditures may boost 1H24 growth.

Portfolio Pulse from Nicolás Jose Rodriguez

November 14, 2023 | 8:58 pm

TGT

Target Corp (NYSE:TGT) is set to report Q3 earnings with an expected EPS of $1.48 and revenue of $25.31 billion. BofA analysts see modest downside risks due to inflation and macro challenges but maintain a Buy rating with a $135 price target. Target's stock has declined 36% over the past year, but improving margins and a low forward price multiple present a buy opportunity. Analysts will focus on macro headwinds and margin improvements in the earnings call.

Portfolio Pulse from Surbhi Jain

November 14, 2023 | 8:54 pm

PXMD

PaxMedica, Inc. (NASDAQ:PXMD) shares are experiencing increased volatility and trading higher on Tuesday, likely influenced by the positive results of their Autism Spectrum Disorder Phase 2 study published on Nov. 7. The study showed significant progress in the CGI-I scale within the 10 mg/kg group compared to the placebo group. The stock's movement may also be attributed to broader market strength following a better-than-expected U.S. inflation report for October.

Portfolio Pulse from Ryan Gustafson

November 14, 2023 | 8:46 pm

ISPR

Ispire Technology (NASDAQ:ISPR) reported a reduced Q1 loss of $(0.04) per share compared to $(0.06) per share YoY, with sales rising to $26.94M from $24.14M in the same quarter last year, indicating a 33.33% improvement in EPS and an 11.63% increase in sales.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 8:45 pm

BAC

WFC

Bank of America Corp (BAC) and Wells Fargo & Co (WFC) shares are trading higher as October CPI data indicated softer-than-expected inflation, leading to overall market strength. The lower inflation rate of 3.2% suggests a potential for interest rate cuts, which is favorable for banks as it can reduce borrowing costs and encourage lending, thereby boosting profitability. BAC and WFC benefit from this environment, as reflected in their share price increase.

Portfolio Pulse from Henry Khederian

November 14, 2023 | 8:45 pm

CLOV

Clover Health Investments, Corp. (NASDAQ:CLOV) shares have experienced volatility throughout November, with a rally in early November ahead of its Q3 earnings report. The company reported sales of $482.07 million, missing estimates, and an earnings loss of nine cents per share, beating expectations. Despite an initial drop post-earnings, CLOV shares rose 11.1% to $1.00, potentially influenced by positive October CPI data indicating easing U.S. inflation.

Portfolio Pulse from Ryan Gustafson

November 14, 2023 | 8:25 pm

RBB

RBB Bancorp disclosed that its internal control over financial reporting and disclosure controls and procedures were not effective as of September 30, 2023. The company has issued corrections to its Q3 earnings release.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 8:24 pm

DCBO

Needham analyst Ryan MacDonald initiated coverage on Docebo Inc (NASDAQ:DCBO) with a Buy rating and a price target of $56. MacDonald highlights Docebo's potential to gain market share and deliver growth and profitability in FY24, citing a differentiated product suite and growth initiatives. Revenue and EPS estimates for FY23 are $180.0 million and $0.58, and for FY24 are $221.4 million and $1.09, respectively. Docebo's Q2 FY23 results exceeded expectations with a 24.8% revenue increase and an adjusted EPS of $0.14. DCBO shares rose 9.35% to $51.64.

Portfolio Pulse from Lekha Gupta

November 14, 2023 | 8:20 pm